AbCellera Biologics (NASDAQ:ABCL) Stock Price Target Raised at Piper Sandler

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) had its price target hoisted by equities research analysts at Piper Sandler from $12.00 to $20.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler‘s target price points to a potential upside of 74.06% from the stock’s current price.

A number of other analysts also recently issued reports on ABCL. UBS Group started coverage on AbCellera Biologics in a research note on Monday, October 12th. They issued a “buy” rating and a $18.00 price objective on the stock. StoneX upped their price objective on AbCellera Biologics from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 11th. Jefferies Financial Group began coverage on AbCellera Biologics in a research report on Friday, October 30th. They set a “buy” rating and a $21.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of AbCellera Biologics in a report on Tuesday, September 29th. They issued an “overweight” rating and a $17.00 target price for the company. Finally, Wall Street Zen raised shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $16.55.

Check Out Our Latest Analysis on ABCL

AbCellera Biologics Price Performance

Shares of AbCellera Biologics stock opened at $11.49 on Monday. AbCellera Biologics has a twelve month low of $2.74 and a twelve month high of $15.02. The business has a 50-day moving average price of $12.34 and a 200-day moving average price of $7.23. The firm has a market cap of $3.75 billion, a price-to-earnings ratio of -23.94 and a beta of 1.59.

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. AbCellera Biologics had a negative return on equity of 15.35% and a negative net margin of 218.54%. The company had revenue of $10.64 million for the quarter, compared to the consensus estimate of $8.42 million. During the same period in the previous year, the business earned ($0.19) earnings per share. On average, equities analysts expect that AbCellera Biologics will post -0.65 EPS for the current fiscal year.

Insider Buying and Selling at AbCellera Biologics

In related news, major shareholder Holdings Ltd. Thermopylae purchased 60,565 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were bought at an average price of $11.54 per share, for a total transaction of $698,920.10. Following the acquisition, the insider owned 56,194,662 shares of the company’s stock, valued at approximately $648,486,399.48. This represents a 0.11% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 28.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Green Alpha Advisors LLC boosted its holdings in AbCellera Biologics by 4.6% during the 3rd quarter. Green Alpha Advisors LLC now owns 22,930 shares of the company’s stock valued at $335,000 after acquiring an additional 1,014 shares during the period. Blume Capital Management Inc. grew its position in AbCellera Biologics by 22.7% in the 3rd quarter. Blume Capital Management Inc. now owns 5,501 shares of the company’s stock valued at $80,000 after acquiring an additional 1,017 shares during the last quarter. ProShare Advisors LLC increased its stake in AbCellera Biologics by 12.2% in the third quarter. ProShare Advisors LLC now owns 11,235 shares of the company’s stock worth $164,000 after purchasing an additional 1,224 shares during the period. SBI Securities Co. Ltd. increased its stake in AbCellera Biologics by 13.7% in the third quarter. SBI Securities Co. Ltd. now owns 14,272 shares of the company’s stock worth $208,000 after purchasing an additional 1,721 shares during the period. Finally, Allworth Financial LP increased its stake in AbCellera Biologics by 35.3% in the third quarter. Allworth Financial LP now owns 15,748 shares of the company’s stock worth $230,000 after purchasing an additional 4,105 shares during the period. 61.42% of the stock is owned by hedge funds and other institutional investors.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

See Also

Analyst Recommendations for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.